Based on historical data, the probability of success for a drug moving from phase 1 of clinical trials to phase 2 stands at about 63 per cent. US stocks surged as investors eyed some encouraging news about a potential coronavirus vaccine. Last month, the Moderna mRNA vaccine showed promising results by generating an immune-system response in the body to fight coronavirus.